Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Lysine acetyltransferase 6A (KAT6A) is a MYST family member vital for development and hematopoiesis.
• KAT6A functions as an oncogene in acute myeloid leukemia (AML), linked to poor prognosis and metastasis.
• KAT6A mutations contribute to cancer progression and therapeutic resistance in various cancers.

Purpose of the Study:

• To review the structural and biological functions of KAT6A.
• To summarize KAT6A's role in the development of diverse tumors.
• To introduce recent KAT6A/B inhibitors, their anticancer activities, and future therapeutic potential.

Main Methods:

• Literature review of structural and biological functions of KAT6A.
• Summary of KAT6A's influence on tumor development.
• Overview of recent research on KAT6A/B inhibitors and their therapeutic applications.

Main Results:

• KAT6A is essential for normal development but acts as an oncogene in AML.
• KAT6A overexpression and mutations are implicated in cancer progression and drug resistance.
• Emerging KAT6A/B inhibitors show promise as anticancer drug candidates.

Conclusions:

• KAT6A plays a dual role in development and oncogenesis.
• Targeting KAT6A presents a potential therapeutic strategy for various cancers.
• Further development of KAT6A/B inhibitors is warranted for clinical application.